VXM 01

Drug Profile

VXM 01

Alternative Names: VEGFR2 peptide vaccine - VAXIMM; VEGFR2 specific T cell vaccine - VAXIMM; VXM-01

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer VAXIMM
  • Class Cancer vaccines; DNA vaccines; Peptide vaccines
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Glioblastoma; Pancreatic cancer
  • Preclinical Solid tumours

Most Recent Events

  • 01 Dec 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the Molecular Targets and Cancer Therapeutics Symposium (EORTC-NCI-AACR-2016)
  • 01 May 2016 Phase-I clinical trials in Glioblastoma (Late-stage disease, Second-line therapy or greater, Recurrent) in Germany (PO) (NCT02718443)
  • 18 Mar 2016 Vaximm plans a pilot phase I trial for Glioblastoma (Late-stage disease, Second-line therapy or greater, Recurrent) in Germany (PO) (NCT02718443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top